Inactive Instrument

Company Metacrine, Inc.

Equities

MTCR

US59101E1038

Biotechnology & Medical Research

Business Summary

Metacrine, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal (GI) diseases. The Company’s advanced program targets the farnesoid X receptor (FXR), which is central to modulating GI and liver diseases. The Company’s pipeline includes MET642 and hydroxysteroid dehydrogenase 17B13 (HSD17B13 or HSD). MET642 is used for the treatment of inflammatory bowel disease (IBD) including ulcerative colitis (UC) and Crohn’s disease. HSD17B13 is used for the treatment of non-alcoholic steatohepatitis (NASH) and other liver diseases. The Company is pursuing the development of MET642 for the treatment of Ulcerative Colitis (UC). The Company has built a proprietary library of approximately 2,500 FXR compounds.

Number of employees: 10

Managers

Managers TitleAgeSince
Chief Executive Officer 64 23-03-23

Members of the board

Members of the board TitleAgeSince
Director/Board Member 61 23-03-22

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 43,832,832 37,228,124 ( 84.93 %) 0 84.93 %

Company contact information

Metacrine, Inc.

4225 Executive Square Suite 600

92037, San Diego

+

http://www.metacrine.com
address Metacrine, Inc.(MTCR)